Safety and Performance of the CG-100 in Patients Undergoing Colorectal Surgery.

Not Applicable

• Conditions: Colorectal Surgery
• Interventions: Device: CG-100 Intraluminal Bypass Device

• Registration Number: NCT03423485
• Lead Sponsor: Colospan Ltd.

Brief Summary

The purpose of this study is to evaluate the CG-100 device, a single use, temporary intraluminal bypass device,intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)

Detailed Description

Colospan is initiating a pivotal clinical prospective, multi-center, single-arm, open-label study designed to evaluate safety and performance profile of the CG-100 Intraluminal Bypass Device in patients undergoing colorectal surgery study.

Up to 137 patients (in total) will be enrolled in up to 12 sites in Europe, Israel and USA.

Study objectives Primary Objective: To evaluate the performance of the CG-100 Intraluminal Bypass Device, in reducing contact of fecal content with an anastomotic site in patients undergoing colorectal surgery (open, robotic, or laparoscopic) Secondary Objectives: To evaluate Performance in terms of clinical and radiological anastomotic leakage Successful positioning and maintenance of device position To assess the ease of the device's application and removal Safety: To assess the safety profile of the CG-100 Intraluminal Bypass Device.

Study Timeline

• Study First Submitted: 2017-12-21
• Status Verified: 2018-01
• Study Start: 2018-01-01
• Study First Submitted QC: 2018-02-04
• Study First Posted: 2018-02-06
• Last Update Submitted: 2018-10-03
• Last Update Posted: 2018-10-04
• Primary Completion: 2019-06-01
• Study Completion: 2019-07-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 137

Inclusion Criteria

1. The patient is willing to comply with protocol-specified follow-up evaluations
2. Patient 22-75 years of age at screening
3. The patient is scheduled to undergo an elective colorectal surgery (open, laparoscopic, or robotic) which will require the creation of an anastomosis, maximally 20 cm proximal from the anal verge
4. The patient or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).

Exclusion Criteria

Preoperative

1. Pregnant or nursing female subjects. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.
2. Patient surgical treatment is acute (not elective)
3. Patient has local or systemic infection at the time of intervention (e.g., peritonitis)
4. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
5. Patients with ASA classification > 3
6. Albumin < 30 g/liter
7. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease
8. BMI ≥ 40
9. Subject is going through another surgical procedure (other than ileostomy or adhesiolysis) during the surgery.
10. Patient is participating in another clinical trial within 30 days of screening
11. Patient has been taking regular steroid medication in the last 6 months.
12. Patient has contraindications to general anesthesia
13. Patient has preexisting sphincter problems
14. Patient has evidence of extensive local disease in the pelvis
15. Any condition which in the opinion of the investigator may jeopardize the patient's safe participation Intraoperative (prior to device deployment)
16. Anastomosis is located more than 20 cm from the anal verge
17. Internal diameter lumen of the colon is smaller than 25 mm or larger than 34 mm
18. Blood loss (> 500 cc)
19. Anastomosis was not performed for any reason other than consequences as a result of use of the study device -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Study arm	CG-100 Intraluminal Bypass Device	Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device

Primary Outcome Measures

Name	Time	Method
To evaluate the performance of the CG-100 Intraluminal Bypass Device, in reducing contact of fecal content with an anastomotic site in patients undergoing colorectal surgery (open, robotic, or laparoscopic)	device removal day (10 days +/-1)	Leak proof seal with at least 85% success at balloon-Mucosa interface as evidenced by contrast through the device lumen without extravasation and no illumination of the anastomosis.

Secondary Outcome Measures

Name	Time	Method
To assess the safety profile of the CG-100 Intraluminal Bypass Device.	Up to 30 (+/- 5) days	Rate of device related complications
To evaluate Performance in terms of clinical anastomotic leakage based on clinical symptoms of the patient such as fever, blood tests.	Device deployment until device removal day (10 days +/-1)	The patient will be followed for 10±1 days to assess the occurrence of clinical anastomotic leakage based on positive clinical symptoms of the patient such as fever, blood tests, while the CG-100 Intraluminal Bypass Device is in situ.; In addition, at 10±1 days a rectal contrast enema will be done to assess the occurrence of radiological anastomotic leakage.
Successful positioning and maintenance of device position	10+1 days post-surgery before device removal	Position of internal sheath during rectal contrast enema based on radiological demonstration
To assess the ease of the device's application and removal	Surgical procedure and Device removal day (10 days +/-1)	Assessment of the ease of the device's application will be done using a Device application use questionnaire completed by the surgeon at Procedure Day. The ease of device removal will also be assessed on Discharge Day, using the Device application use questionnaire
To assess the occurrence of radiological anastomotic leakage, evaluated by performing a rectal contrast enema .	At 10±1 days	At 10±1 days a rectal contrast enema will be done to assess the occurrence of radiological anastomotic leakage.

Trial Locations

Locations (5)

CHUV, University Hospital Vaudois; 🇨🇭 Lausanne, Switzerland

Carmel Medical Center; 🇮🇱 Haifa, Israel

Hospital Beaujon; 🇫🇷 Paris, Clichy, France

University Hospital of Hamburg; 🇩🇪 Hamburg, Germany

Soroka Medical Center; 🇮🇱 Beer-Sheva, Israel